TY - JOUR
AU - R. L. Cooper
AU - R. D. Edgerton
AU - J. Watson
AU - N. Conley
AU - W. A. Agee
AU - D. M. Wilus
AU - S. A. MacMaster
AU - L. Bell
AU - P. Patel
AU - A. Godbole
AU - C. Bass-Thomas
AU - A. Ramesh
AU - M. Tabatabai
A1 - 
AB - Background: Currently, the capacity to provide buprenorphine treatment (BT) is not sufficient to treat the growing number of people in the United States with opioid use disorder (OUD). We sought to examine participant retention in care rates of primary care delivered BT programs and to describe factors associated with retention/attrition for participants receiving BT in this setting.Objectives: A PRISMA-guided search of various databases was performed to identify the articles focusing on efficacy of BT treatment and OUD.Method: A systematic literature search identified 15 studies examining retention in care in the primary care setting between 2002 and 2020. Random effects meta-regression were used to identify retention rates across studies.Results: Retention rates decreased across time with a mean 0.52 rate at one year. Several factors were found to be related to retention, including: race, use of other drugs, receipt of counseling, and previous treatment with buprenorphine.Conclusions: While we only investigate BT through primary care, our findings indicate retention rates are equivalent to the rates reported in the specialty care literature. More work is needed to examine factors that may impact primary care delivered BT specifically and differentiate participants that may benefit from care delivered in specialty over primary care as well as the converse.
AD - Department of Family and Community Medicine, Meharry Medical College, Nashville, TN, USA.; College of Public Health, University of Kentucky, Lexington, KY, USA.; Mental Health Cooperative, Nashville, TN, USA.; Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, USA.; School of Graduate Studies & Research, Meharry Medical College, Nashville, TN, USA.; Department of Biochemistry, Cancer Biology, Neuroscience & Pharmacology, Meharry Medical College, Nashville, TN, USA.
AN - 37737714
BT - Am J Drug Alcohol Abuse
C5 - Opioids & Substance Use
CP - 6
DA - Nov 2
DO - 10.1080/00952990.2023.2251653
DP - NLM
ET - 20231211
IS - 6
JF - Am J Drug Alcohol Abuse
LA - eng
N2 - Background: Currently, the capacity to provide buprenorphine treatment (BT) is not sufficient to treat the growing number of people in the United States with opioid use disorder (OUD). We sought to examine participant retention in care rates of primary care delivered BT programs and to describe factors associated with retention/attrition for participants receiving BT in this setting.Objectives: A PRISMA-guided search of various databases was performed to identify the articles focusing on efficacy of BT treatment and OUD.Method: A systematic literature search identified 15 studies examining retention in care in the primary care setting between 2002 and 2020. Random effects meta-regression were used to identify retention rates across studies.Results: Retention rates decreased across time with a mean 0.52 rate at one year. Several factors were found to be related to retention, including: race, use of other drugs, receipt of counseling, and previous treatment with buprenorphine.Conclusions: While we only investigate BT through primary care, our findings indicate retention rates are equivalent to the rates reported in the specialty care literature. More work is needed to examine factors that may impact primary care delivered BT specifically and differentiate participants that may benefit from care delivered in specialty over primary care as well as the converse.
PY - 2023
SN - 0095-2990
SP - 756
EP - 765+
ST - Meta-analysis of primary care delivered buprenorphine treatment retention outcomes
T1 - Meta-analysis of primary care delivered buprenorphine treatment retention outcomes
T2 - Am J Drug Alcohol Abuse
TI - Meta-analysis of primary care delivered buprenorphine treatment retention outcomes
U1 - Opioids & Substance Use
U3 - 10.1080/00952990.2023.2251653
VL - 49
VO - 0095-2990
Y1 - 2023
ER -